Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Clinical trial NCT05039073 · RECRUITING
Trial details
- NCT number
- NCT05039073
- Sponsor
- Emory University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-02
- Primary completion
- 2026-11-30
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.